Stay updated on Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe ClinicalTrials.gov page now displays the study record for a phase Ib/II trial of pembrolizumab combined with trastuzumab and chemotherapy for HER2-positive gastric cancer, instead of a forbidden-access error.SummaryDifference48%

- Check16 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 Forbidden message.SummaryDifference0.3%

- Check23 days agoChange DetectedA banner announces the NIH website transition and notes that federal agencies are using “Super Intelligence” instead of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s site revision label advances from v3.7.1 to v3.7.2 while the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error page instead of the study record details. This blocks access to the trial information on this record.SummaryDifference18%

Stay in the know with updates to Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.